Daiwa Securities Group Inc. Avidity Biosciences, Inc. Transaction History
Daiwa Securities Group Inc.
- $22.4 Billion
- Q4 2024
A detailed history of Daiwa Securities Group Inc. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 2,282 shares of RNA stock, worth $66,543. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,282
Previous 2,107
8.31%
Holding current value
$66,543
Previous $97,000
31.96%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding RNA
# of Institutions
257Shares Held
108MCall Options Held
517KPut Options Held
717K-
Price T Rowe Associates Inc Baltimore, MD11MShares$322 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$275 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$251 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.11MShares$236 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY7.93MShares$231 Million3.76% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.52B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...